Day: April 3, 2023

Navitas and realme Launched World’s First 240W Ultra-Fast Charging Phone at MWC

Written by Customer Service on . Posted in Public Companies.

Next-gen gallium nitride (GaN) drives ‘Speed to the Max’ SUPERVOOC milestone, with 100% charge in under ten minutes Navitas and realme Launched World’s First 240W Ultra-Fast Charging Phone at MWC Next-gen gallium nitride (GaN) drives ‘Speed to the Max’ SUPERVOOC milestone, with 100% charge in under ten minutes TORRANCE, Calif., April 03, 2023 (GLOBE NEWSWIRE) — Navitas Semiconductor (Nasdaq: NVTS), the only pure-play, next-generation power semiconductor company, has announced that its next-generation GaNFast™ technology has been adopted for the ‘in-box’ 240 W ultra-fast charger provided with the recently-announced realme GT3 smartphone. Launched at this year’s Mobile World Conference (MWC), realme’s GT3 is a powerful and stylish new Android device and the world’s first smartphone to offer the power of 240 W charging....

Continue reading

Panbela Announces New Research Agreement with Johns Hopkins University School of Medicine

Written by Customer Service on . Posted in Public Companies.

MINNEAPOLIS, April 03, 2023 (GLOBE NEWSWIRE) — Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients with cancer, today announced a new research agreement with the Johns Hopkins University School of Medicine. The collaboration is intended to expand the development of Panbela’s investigative agent ivospemin (SBP-101), including activity in models of ovarian and other cancer types, further evaluations into mechanism of action, and potential combination with CPP-1X and standard of care agents. The research will be co-led by Robert Casero, Ph.D., professor, and Tracy Murray Stewart, Ph.D., Senior Research Scientist, both in oncology at Johns Hopkins University School of Medicine. Prof. Casero and Dr. Murray Stewart are internationally recognized...

Continue reading

HBT Financial, Inc. Announces Executive Officer Transition Plans

Written by Customer Service on . Posted in Public Companies.

BLOOMINGTON, Ill., April 03, 2023 (GLOBE NEWSWIRE) — HBT Financial, Inc. (NASDAQ: HBT) (the “Company” or “HBT”), the holding company for Heartland Bank and Trust Company (“Heartland Bank”), today announced that Fred L. Drake, Chairman and CEO of the Company and Chairman of Heartland Bank, will transition to the newly created role of Executive Chairman of the Company and Heartland Bank effective May 24, 2023. At that time, J. Lance Carter, President and Chief Operating Officer of the Company and Heartland Bank, will assume the role of President and CEO of the Company and Heartland Bank. Fred Drake stated, “I am very pleased to have Lance Carter assume responsibility as CEO of HBT Financial and Heartland Bank. In recent years, Lance has demonstrated the capability to lead HBT into the future.  Over his 22-year career with us, he...

Continue reading

RespireRx Pharmaceuticals Inc. Discloses Novel Structural Analogs of its GABAA Receptor Potentiator, KRM-II-81 with Antiseizure Efficacy and Antitremor Effects without Sedation.

Written by Customer Service on . Posted in Public Companies.

Glen Rock, N.J., April 03, 2023 (GLOBE NEWSWIRE) — RespireRx Pharmaceuticals Inc. (OTC Markets: RSPI) (“RespireRx” or the “Company”), a leader in the discovery and development of innovative and revolutionary treatments to combat diseases caused by disruption of neuronal signaling, is pleased to announce the publication of four articles describing the pharmacological activity of novel structural analogs of KRM-II-81, the Company’s lead GABAkine. Like KRM-II-81, these analogs enhance GABAergic neurotransmission and function as orally-bioavailable anti-seizure agents in the absence of the sedation typically associated with GABA augmentation. KRM-II-81, itself, has been shown to be effective across a broad array of anti-seizure models including those predicting efficacy in patients that are pharmaco-resistant and in brain tissue from...

Continue reading

GOLD LION ENGAGES GEOLOGICA GROUPE-CONSEIL FOR 2023 FIELDWORK AT MIA LI-3 LITHIUM PROJECT

Written by Customer Service on . Posted in Public Companies.

Vancouver, British Columbia, April 03, 2023 (GLOBE NEWSWIRE) — Gold Lion Resources Inc. (“Gold Lion” or the “Company”) (CSE: GL) (OTC: GLIOF) (FWB: 2BC) is pleased to announce plans it has engaged Geologica Groupe-Conseil of Val d’or, QC (“Geologia”) as its technical fieldwork partner for its 2023 exploration campaign (the “2023 Campaign”) at its Mia Li-3 Lithium Project. The Company’s 2023 Campaign will include the following: historical data compilation and review of high-resolution satellite imagery at the Mia Li-3 Lithium Property; and, extensive fieldwork program which will include detailed mapping and sampling campaign at the Mia Li-3 Lithium Property soon as weather and snow cover permits. The detailed groundwork will provide guidance on the extent of lithium mineralization; and, follow-on maiden drilling campaign...

Continue reading

Haydock Finance Goes Live with Flex – NETSOL’s Cloud-Based Calculation Engine

Written by Customer Service on . Posted in Public Companies.

CALABASAS, Calif., April 03, 2023 (GLOBE NEWSWIRE) — NETSOL Technologies, Inc. (Nasdaq: NTWK), a global business services and enterprise application solutions provider, has announced that Haydock Finance has signed up for and gone live with Flex – NETSOL’s API-first and cloud-based calculation engine. The sign-up and go-live covers the deployment of Flex for the business finance provider in the United Kingdom. “Flex was launched as the first product of ‘Appex Now’, which is essentially the first marketplace developed specifically for the global credit, finance and leasing industry by NETSOL,” said Najeeb Ghauri, Founder and CEO of NETSOL Technologies, Inc. “While more products are to be launched as part of the marketplace, it gives me great pleasure that Haydock Finance has signed-up and gone live with our calculation engine...

Continue reading

Maris-Tech Completes its Share Repurchase Program

Written by Customer Service on . Posted in Public Companies.

The company acquired 1.5% of its ordinary shares. REHOVOT, Israel, April 03, 2023 (GLOBE NEWSWIRE) — Maris-Tech Ltd. (Nasdaq: MTEK, MTEKW) (“Maris-Tech” or the “Company”), a B2B provider of intelligent video transmission technology with artificial intelligence (AI) acceleration for edge platforms, today announces that its previously announced share repurchase program (the “Repurchase Program”) was completed on March 31, 2023. The Company repurchased 120,715 of its ordinary shares, no par value per share (the “Ordinary Shares”), representing approximately 1.5% of its issued and outstanding Ordinary Shares, at an average price of $0.987 per Ordinary Share. About Maris-Tech Ltd. Maris-Tech is a B2B provider of intelligent video transmission technology, founded by veterans of the Israel technology sector with extensive...

Continue reading

Recursion to Participate in Upcoming Investor Conference

Written by Customer Service on . Posted in Public Companies.

Salt Lake City, April 03, 2023 (GLOBE NEWSWIRE) — Recursion (NASDAQ: RXRX), a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery, today announced its participation in the following investor conference: 22nd Annual Needham Virtual Healthcare Conference – April 17 through April 20, 2023 About Recursion Recursion is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest proprietary biological and chemical datasets. Recursion leverages sophisticated machine-learning algorithms to distill from its dataset a collection of trillions of searchable relationships across biology and chemistry unconstrained...

Continue reading

CPI-818 Data Highlights Potential for ITK Inhibition as a New Immunotherapy Approach for the Treatment of T Cell Lymphoma

Written by Customer Service on . Posted in Public Companies.

Interim data from Phase 1/1b clinical trial of CPI-818, including new evidence supporting the recently implemented minimum absolute lymphocyte count (ALC) predictive biomarker Data presented at the 10th Whistler Global Summit on Hematologic Malignancies BURLINGAME, Calif., April 03, 2023 (GLOBE NEWSWIRE) — Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, today announced interim data demonstrating the potential of CPI-818, the Company’s ITK inhibitor, for the treatment of T cell lymphoma (TCL) at the 10th Whistler Global Summit on Hematologic Malignancies, which took place March 29 to April 2, 2023 in Whistler British Columbia, Canada. The CPI-818 data was presented by John Reneau, MD, PhD, from The Ohio State University Comprehensive Cancer Center. Dr. Reneau is a hematologist who specializes...

Continue reading

ContraFect Announces Initiation of a Phase 1b/2 Study of Exebacase in Patients with Chronic Prosthetic Joint Infections of the Knee

Written by Customer Service on . Posted in Public Companies.

YONKERS, New York, April 03, 2023 (GLOBE NEWSWIRE) — ContraFect Corporation (Nasdaq: CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections, announced the initiation of a Phase 1b/2 of exebacase in the setting of an arthroscopic debridement, antibiotics, irrigation, and retention (DAIR) procedure in patients with chronic prosthetic joint infections (PJI) of the knee due to Staphylococcus aureus (S. aureus) or Coagulase-Negative Staphylococci (CoNS). “With the initiation of this trial, we have reached yet another significant milestone for the company in a short period of time. This study of exebacase in patients with chronic PJI provides...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Cookie Notice

We use cookies to improve your experience on our website

Information we collect about your use of Goldea Capital website

Goldea Capital website collects personal data about visitors to its website.

When someone visits our websites, we use a third party service, Google Analytics, to collect standard internet log information (such as IP address and type of browser they’re using) and details of visitor behavior patterns. We do this to allow us to keep track of the number of visitors to the various parts of the sites and understand how our website is used. We do not make any attempt to find out the identities or nature of those visiting our websites. We won’t share your information with any other organizations for marketing, market research or commercial purposes and we don’t pass on your details to other websites.

Use of cookies
Cookies are small text files that are placed on your computer or other device by websites that you visit. They are widely used to make websites work, or work more efficiently, as well as to provide information to the owners of the site.